SCHEMBL6775434

SCHEMBL6775434

Cc1cccc(Cn2c3cc(-c4ccc(Cl)cc4)cc(O)c3c3c(C(N)=O)cccc32)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.46
PLA2G2A P14555 5/20 0.46
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
F10 P00742 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PARP1 P09874 2/20 0.38
PARP2 Q9UGN5 2/20 0.38
BRD4 O60885 2/20 0.37
CNR1 P21554 1/20 0.37
PLA2G1B P04054 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
ICMT O60725 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774185 0.91 TP53 (0.47) ADRA1DPLA2G2AALDH1A1MAPTTP53
SCHEMBL6776758 0.91 PLA2G2A (0.50) ADRA1DPLA2G2AALDH1A1KDM4EMAPT
SCHEMBL6690216 0.91 PLA2G2A (0.43) ADRA1DPLA2G2AALDH1A1POLBMEN1
SCHEMBL6776773 0.89 PLA2G2A (0.42) PLA2G2AALDH1A1PLA2G1B
SCHEMBL6890338 0.89 MAPT (0.44) PLA2G2AALDH1A1KDM4EMAPTTP53
SCHEMBL6776710 0.88 PLA2G2A (0.41) ADRA1DPLA2G2AF10L3MBTL1PARP1
SCHEMBL6772770 0.88 PLA2G2A (0.41) ADRA1DPLA2G2AALDH1A1KDM4EMAPT
SCHEMBL6771677 0.87 PLA2G2A (0.41) ADRA1DPLA2G2AALDH1A1L3MBTL1PLA2G1B
SCHEMBL6691732 0.87 ADRA1D (0.44) ADRA1DPLA2G2AALDH1A1MAPTPOLB
SCHEMBL6775381 0.86 PPARG (0.44) PLA2G2AMAPTF10L3MBTL1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed